Abbott's Assert-IQ Redefines Arrhythmia Management

Abbott, a leading global healthcare company, has launched its newest medical device, Assert-IQ ICM, providing physicians with an advanced tool for evaluating arrhythmia and facilitating long-term monitoring. Assert-IQ ICM is designed for minimally invasive implantation, assisting physicians in the continuous monitoring and diagnosis of arrhythmias, which are often transient in nature. 

An arrhythmia is when the heartbeat's rate or rhythm is abnormal, causing irregular heartbeats due to fast, slow, or erratic electrical impulses, as reported by the American Health Association. Cardiac arrhythmias, particularly atrial fibrillation (AFib), are prevalent and potentially life-threatening conditions affecting millions worldwide. The global prevalence of AFib, the most common heart arrhythmia, exceeds 33.5 million people, with projections indicating a continued rise over the next three decades, as reported by Abbott. To tackle this challenge, the introduction of Assert-IQ represents a significant advancement in arrhythmia management.

The Assert-IQ enables continuous heart monitoring, crucial for detecting arrhythmias that may lead to symptoms like fainting and shortness of breath. This capability is enabled through its Bluetooth technology, allowing the device to connect to a transmitter, typically the patient's own cell phone, to monitor heart rhythms every 20 seconds. This real-time monitoring transmits essential findings directly to the clinic's portal, facilitating prompt medical intervention. Additionally, Assert-IQ boasts the world's longest battery life among Bluetooth-enabled ICMs, offering either a three-year or six-year option to accommodate varying monitoring needs.

Leonard Ganz, Divisional Vice President of Medical Affairs and Chief Medical Officer for Abbott's Cardiac Rhythm Management Division, emphasized the significance of Assert-IQ's introduction. "As the prevalence of abnormal heart rhythms rises, physicians increasingly rely on ICM technology to diagnose various heart conditions," he stated. Ganz also underscored how Assert-IQ expands access to long-term monitoring benefits, providing clinicians with more relevant data for faster and more precise clinical decisions.

The advanced algorithms of Assert-IQ not only reduce data burden but also enhance device accuracy, streamlining physician workflow and efficiency. "Assert-IQ is the next generation of implantable cardiac monitors, providing physicians with actionable data and new patient insights," said Paolo Della Bella, Head of the Arrhythmia Department, IRCCS San Raffaele Scientific Institute. He also emphasized how real-time data, advanced algorithms, and diagnostic accuracy empower physicians to deliver personalized and effective care, offering peace of mind for those with abnormal heart rhythms.